Received Feb 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Underdose; during the administration of Boostrix part of the liquid came out; pharmaceutical product complaint; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of underdose in a patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. On an unknown date, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced underdose (Verbatim: Underdose), product leakage (Verbatim: during the administration of Boostrix part of the liquid came out) and pharmaceutical product complaint (Verbatim: pharmaceutical product complaint). The outcome of the underdose, product leakage and pharmaceutical product complaint were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt date: 13-FEB-2026. The pharmacist was asked as general question, what was the recommendations on this situation. Did the patient had to get revaccinated The batch number was not provided, and we are unable to contact the reporter.